Spruce Biosciences, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-16.2M | $-12.3M | $-14.6M | $-8.2M | $-2.1M | $-14.0M | $-23.6M | $-8.7M |
| Depreciation & Amortization | $631.0K | $252.0K | $5.0K | $3.0K | $7.0K | $6.0K | $9.0K | $10.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $871.0K | $689.0K | $1.7M | $415.0K | $-77.0K | $544.0K | $961.0K | $1.1M |
| Net Cash from Operating Activities | $-22.1M | $-8.7M | $-6.5M | $-5.3M | $-8.8M | $-12.7M | $-20.7M | $-9.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $135.0K | $10.0K | — | — | $0 | $0 | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-135.0K | $-10.0K | — | — | $0 | $0 | $0 | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $64.5M | $13.9M | $44.7M | $-402.0K | $-400.0K | $-411.0K | $-625.0K | $-405.0K |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-22.3M | $-8.7M | — | — | $-8.8M | $-12.7M | — | — |